ReviewSeminars in cancer biology2015
A multi-targeted approach to suppress tumor-promoting inflammation.
Review in Seminars in cancer biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- Deciphering the Shared Mechanisms Underlying the Effects of Osthole on the Inflammation-Cancer Axis: An Integrative Network Pharmacology and Molecular Dynamics Study.Current issues in molecular biology · 2026Article
- Causal relationship between oral/gut microbiota and lung cancer: a two-sample Mendelian randomization study.Discover oncology · 2025Article
- The immunological pathogenesis of vitiligo and the potential role of mesenchymal stromal/stem cells in its treatment.Journal of translational medicine · 2025Review
- MicroRNAs as Potential Biomarkers of Environmental Exposure to Polycyclic Aromatic Hydrocarbons and Their Link with Inflammation and Lung Cancer.International journal of molecular sciences · 2023Review
- Genomic-driven nutritional interventions for radiotherapy-resistant rectal cancer patient.Scientific reports · 2023Article
- Role of Antioxidant Vitamins and Other Micronutrients on Regulations of Specific Genes and Signaling Pathways in the Prevention and Treatment of Cancer.International journal of molecular sciences · 2023Review
- The Extract ofFoods (Basel, Switzerland) · 2023Article
- Interplay between stress and cancer-A focus on inflammation.Frontiers in physiology · 2023Review
- Immunomodulatory Role of Thioredoxin Interacting Protein in Cancer's Impediments: Current Understanding and Therapeutic Implications.Vaccines · 2022Review
- Patients with Lung Cancer of Different Racial Backgrounds Harbor Distinct Immune Cell Profiles.Cancer research communications · 2022Article
- Tumor-promoting inflammation in lung cancer: A literature review.Annals of medicine and surgery (2012) · 2022Review
- Mutually Exclusive Expression of COL11A1 by CAFs and Tumour Cells in a Large panCancer and a Salivary Gland Carcinoma Cohort.Head and neck pathology · 2022Article
- Article
- Tackling heterogeneity in treatment-resistant breast cancer using a broad-spectrum therapeutic approach.Cancer drug resistance (Alhambra, Calif.) · 2022Article
- Combinatorial treatments of tamoxifen and SM6Met, an extract fromFrontiers in pharmacology · 2022Article
- Anti-apoptotic effect of Buchholzia coriacea Engl. stem back extracts on AsPC-1 and mechanisms of action.BMC complementary medicine and therapies · 2021Article
- Employing hydrogels in tissue engineering approaches to boost conventional cancer-based research and therapies.RSC advances · 2021Review
- Biomaterial-Facilitated Immunotherapy for Established Oral Cancers.ACS biomaterials science & engineering · 2021Article
- Inflammation and Alzheimer's Disease: Mechanisms and Therapeutic Implications by Natural Products.Mediators of inflammation · 2021Review
- The mechanism and candidate compounds of aged citrus peel (Food & nutrition research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Funding
Abstract
Cancers harbor significant genetic heterogeneity and patterns of relapse following many therapies are due to evolved resistance to treatment. While efforts have been made to combine targeted therapies, significant levels of toxicity have stymied efforts to effectively treat cancer with multi-drug combinations using currently approved therapeutics. We discuss the relationship between tumor-promoting inflammation and cancer as part of a larger effort to develop a broad-spectrum therapeutic approach aimed at a wide range of targets to address this heterogeneity. Specifically, macrophage migration inhibitory factor, cyclooxygenase-2, transcription factor nuclear factor-κB, tumor necrosis factor alpha, inducible nitric oxide synthase, protein kinase B, and CXC chemokines are reviewed as important antiinflammatory targets while curcumin, resveratrol, epigallocatechin gallate, genistein, lycopene, and anthocyanins are reviewed as low-cost, low toxicity means by which these targets might all be reached simultaneously. Future translational work will need to assess the resulting synergies of rationally designed antiinflammatory mixtures (employing low-toxicity constituents), and then combine this with similar approaches targeting the most important pathways across the range of cancer hallmark phenotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.